Mariner LLC Takes $573,000 Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Mariner LLC bought a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 33,419 shares of the biotechnology company's stock, valued at approximately $573,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC purchased a new position in shares of ADMA Biologics during the 3rd quarter valued at about $61,858,000. Raymond James Financial Inc. purchased a new position in shares of ADMA Biologics during the fourth quarter worth approximately $19,076,000. EWG Elevate Inc. bought a new stake in shares of ADMA Biologics in the 4th quarter worth approximately $480,000. Allspring Global Investments Holdings LLC boosted its stake in shares of ADMA Biologics by 1,144.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company's stock valued at $51,016,000 after purchasing an additional 2,613,482 shares in the last quarter. Finally, Veracity Capital LLC grew its holdings in shares of ADMA Biologics by 117.0% during the 4th quarter. Veracity Capital LLC now owns 46,415 shares of the biotechnology company's stock valued at $796,000 after purchasing an additional 25,030 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Trading Down 1.3 %

Shares of ADMA opened at $23.80 on Thursday. The firm has a fifty day simple moving average of $19.29 and a two-hundred day simple moving average of $18.40. ADMA Biologics, Inc. has a twelve month low of $6.52 and a twelve month high of $25.67. The stock has a market capitalization of $5.66 billion, a P/E ratio of 85.00 and a beta of 0.53. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.